Clinical Trials in Ovarian Cancer by Christine S. Walsh

Author:Christine S. Walsh
Language: eng
Format: epub
Publisher: Rutgers University Press

Chemotherapy

G3/4 toxicity

49%

40%

P = .06

G3/4 neutropenia

20%

16%

G, grade; HR, hazard ratio; NS, not significant; PFS, progression-free survival; OS, overall survival.

COMMENTS

There were no subgroups that benefited more or less from primary chemotherapy.

Debulking to <1 cm residual disease was achieved in 41% with primary surgery and 73% with primary chemotherapy (P = .001). Debulking to no macroscopic residual was achieved in 17% with primary surgery and 39% with primary chemotherapy (P = .001).

Volume of residual disease was prognostic in both groups (data are in appendix of paper).

Quality of life was slightly higher for patients receiving primary chemotherapy than patients receiving primary surgery at 6 at 12 months. Improvement of global quality of life of at least 5 points was higher in patients receiving primary chemotherapy at 6 and 12 months, but the differences were not significant.

The median survival of 22 to 24 months was lower than expected. Some potential explanations:Older median age of patients (65 years).

77% of tumors were poorly differentiated.

19% of patients had performance status of 2 or 3.

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.